CLL Coverage from Every Angle

Kerry A. Rogers, MD, on Chronic Lymphocytic Leukemia: Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed or Refractory Disease

Posted: Monday, August 12, 2019

Kerry A. Rogers, MD, of The Ohio State University, discusses phase II study findings on patients with CLL who discontinued ibrutinib due to adverse events—a common problem for older patients—and how using the more selective treatment acalabrutinib may be of benefit.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.